Talmapimod

Drug Profile

Talmapimod

Alternative Names: SCIO-469

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Scios
  • Class Analgesics; Anti-inflammatories; Antirheumatics; Indoles; Skin disorder therapies
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Skin disorders
  • Discontinued Dental pain; Multiple myeloma; Myelodysplastic syndromes; Rheumatoid arthritis

Most Recent Events

  • 29 Oct 2008 Final efficacy, adverse events & pharmacokinetics data from the phase II SPRiNG trial in Rheumatoid arthritis presented at the 72nd Annual Scientific Meeting of the American College of Rheumatology and the 43rd Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2008)
  • 29 Apr 2005 Phase-I/II clinical trials in Myelodysplastic syndromes in USA (PO)
  • 24 Jan 2005 Preclinical trials in Multiple myeloma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top